Global Health Ventures Successfully Completes Final Version of Its Prototype X-Excite, Its Male Sexual Enhancement Drug

VANCOUVER, BRITISH COLUMBIA--(Marketwire - February 02, 2010) - Global Health Ventures Inc. (OTCBB: GHLV) (the "Company") is pleased to announce that it has successfully completed the prototype preparation of its sublingual X-Excite pill. With the combined efforts of its contract manufacturers (Pharmex Rom Industries) and Globe Labs, Global Health Ventures has been able to resolve the final hurdle being the hardness of the pill and the length of time it took for the pill to disintegrate under the tongue. Now Global Health is pleased to announce that they have the final color and taste of the tablet, and managed to meet their end goal of having a tablet that dissolves in less than 60 seconds under the tongue.

"We are very pleased that the final hurdle in manufacturing the X-Excite pill is behind us. We will now aggressively move forward to the full manufacturing stage for initiating our human clinical trials. 2010 should be a very exciting year for us as we move our products from concept through human trials and closer to commercialization," said Dr. Hassan Salari, Global Health President and CEO.

About Global Health Ventures

The Company is a specialty pharma focused on the life style products. The Company is developing a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy.

Notice Regarding Forward Looking Statements

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.